Answers are grounded in this paper and cite their sources.
Prospective comparative case-control study evaluates TWEAK as a biomarker in psoriasis and psoriatic arthritis treatment response, indicating its utility.
Elevated TWEAK reflects psoriasis and PsA activity. Adalimumab and methotrexate reduce TWEAK alongside clinical improvement, supporting its potential as a biomarker for treatment monitoring. Key Points • Serum TWEAK levels were substantially elevated in psoriasis and psoriatic arthritis patients in comparison to controls. • TWEAK levels decreased following treatment with methotrexate and adalimumab. • Clinical improvement and disease activity scores were positively correlated with a decrease in TWEAK levels. • TWEAK may be a valuable biomarker for the monitoring of treatment response in psoriasis.
No takes yet. Share an insight, caveat, or question.
Hegazy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: